Sunvozertinib for EGFR Exon 20 Insertion NSCLC: Across Pretreated and First-Line Settings

The presentation highlights clinical trials evaluating sunvozertinib as a targeted therapy for non-small cell lung cancer patients with specific EGFR mutations. The first study demonstrates its robust antitumor efficacy and safety profile in patients previously treated with platinum-based chemotherapy. The second study shows that sunvozertinib significantly improves progression-free survival and overall response rates compared to standard chemotherapy when used as a first-line treatment. Overall, these findings support its effectiveness as a manageable and favorable therapeutic option for this patient population.